INTRA-CELLULAR THERAPIES, INC.

Lobbying for INTRA-CELLULAR THERAPIES, INC. · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · New York · House · Senate · $70,000.00 expenses · posted Apr 21, 2025

Bills named in this filing 2

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1990
American Innovation and R&D Competitiveness Act of 2025

Lobbying activity 2

Medicare/Medicaid

H.R. 1492 - EPIC Act: Provisions regarding harmonizing small and large molecule period in the Inflation Reduction Act.

Taxation/Internal Revenue Code

H.R. 1990 - American Innovation and R&D Competitiveness Act: Provisions regarding Section 174 research and development tax credit amortization.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.